Compare JetBlue Airways Corporation (JBLU) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Organon & Co. Common Stock — how do they compare? JetBlue Airways Corporation trades at $3.03 (market cap $1.26B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 2.9× JetBlue Airways Corporation's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Organon & Co. Common Stock for 0 Days on average.
| JBLU | OGN | |
|---|---|---|
Market Cap | $1.26B | $3.62B |
Volume | 40,642,525 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $6.46 | $13.81 |
52-Week Low | $3.01 | $5.70 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $8.63B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.01, down 16.85% in the last 24 hours, reflecting significant bearish pressure. The stock exhibits weak fundamentals with a negative net income margin of -9.32% and consecutive quarterly losses, though it beat EPS expectations in Q2 2026. Technical indicators are predominantly bearish, with the stock trading near key support levels. Recent news highlights expansion efforts like new routes to Colombia and the launch of BlueFirst premium seating, aiming to boost revenue amid industry challenges.
The outlook remains challenging due to persistent losses, high debt levels, and elevated fuel costs. While analyst consensus suggests a hold rating with a $5.89 price target implying potential upside, risks from competitive pressures and macroeconomic factors dominate. Investment appeal is limited to speculative positions betting on a operational turnaround despite current headwinds.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
